1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,116 | 0,124 | 11.11. | |
| 0,116 | 0,124 | 11.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 13:42 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| Fr | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PRESENTS LATE-BREAKING DATA FROM PHASE 2 ENRICH AND ENHANCE STUDIES AT AASLD 2026 | 1 | HKEx | ||
| 04.11. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 5 | HKEx | ||
| 28.10. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 20.10. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 15.10. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT LAUNCH OF BRISC, AN SIRNA THERAPEUTICS DISCOVERY PLATFORM | - | HKEx | ||
| 09.10. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.10. | BRII-B (02137): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | - | HKEx | ||
| 17.09. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 17.09. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 17.09. | BRII-B (02137): 2026 INTERIM REPORT | 1 | HKEx | ||
| 16.09. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 24.08. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 21.08. | Brii Biosciences H1 Loss Narrows, Stock Up | 2 | RTTNews | ||
| 21.08. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results | 350 | PR Newswire | Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026
Emerging Discovery Programs Build Momentum
BRII-5395... ► Artikel lesen | |
| 21.08. | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 07.08. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.07. | Brii Bio reports mixed results from hepatitis B studies | 3 | Investing.com | ||
| 03.07. | Brii Biosciences Limited: Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B | 215 | PR Newswire | End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses... ► Artikel lesen | |
| 03.07. | BRII-B (02137): INSIDE INFORMATION ANNOUNCES TOPLINE END-OF-TREATMENT DATA FROM PHASE 2B ENRICH AND ENHANCE STUDIES FOR THE TREATMENT OF CHRONIC HEPATITIS ... | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 225,45 | -0,60 % | Biogen Inc.: ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure | Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP... ► Artikel lesen | |
| ILLUMINA | 197,82 | +2,77 % | Illumina Inc. Bottom Line Rises In Q3 | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) announced a profit for its third quarter that Increases, from last yearThe company's bottom line came in at $220 million, or $1.43 per share. This... ► Artikel lesen | |
| NANOREPRO | 1,390 | -9,15 % | Original-Research: NanoRepro AG (von NuWays AG): KAUFEN | Original-Research: NanoRepro AG - von NuWays AG
03.11.2026 / 09:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| CYTODYN | 0,190 | 0,00 % | CytoDyn Inc.: CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors | ||
| IMMUNIC | 7,378 | +1,79 % | Immunic vor richtungsweisenden Phase-III-Daten bei Multipler Sklerose | ||
| ADAPTIVE BIOTECHNOLOGIES | 26,220 | -0,30 % | Adaptive Biotechnologies raises 2026 MRD revenue guide to $276M-$286M as it targets $1,700-$1,800 ASP | ||
| GENPREX | 2,120 | +1,44 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| PERSONALIS | 14,250 | +1,60 % | Personalis, Inc.: Personalis NeXT Personal Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026 | Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer
Personalis... ► Artikel lesen | |
| VITROLIFE | 10,570 | -1,77 % | Vitrolife AB: Elin Frostehav appointed CEO of Vitrolife Group | Vitrolife AB (publ) ("Vitrolife Group") today announces the appointment of Elin Frostehav as President and Chief Executive Officer, effective May 1, 2027, or such earlier date as may be determined.... ► Artikel lesen | |
| PLURI | 4,660 | -100,00 % | Pluri CDMO Business Adds Two ISO Certifications | ||
| LEGEND BIOTECH | 17,600 | -3,83 % | Legend Biotech shares fall 16% after first earnings report under new CEO | ||
| ENVERIC BIOSCIENCES | 1,510 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ENANTA | 9,950 | +0,51 % | Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences | Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced... ► Artikel lesen | |
| NATURAL ALTERNATIVES INTERNATIONAL | 0,800 | -13,04 % | Natural Alternatives International Inc: Natural Alternatives International, Inc. Announces Fiscal 2026 Q4 and YTD Results | CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements... ► Artikel lesen | |
| MONOPAR THERAPEUTICS | 65,60 | +2,18 % | H.C. Wainwright reiterates Buy rating on Monopar stock at $125 |
BRII BIOSCIENCES LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,004 (+3,39 %) liegt der Kurs bei 0,122 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.